EQL PHARMA AB (7JK) - Total Assets
Based on the latest financial reports, EQL PHARMA AB (7JK) holds total assets worth €850.89 Million EUR (≈ $994.78 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
EQL PHARMA AB - Total Assets Trend (2022–2026)
This chart illustrates how EQL PHARMA AB's total assets have evolved over time, based on quarterly financial data. Also see EQL PHARMA AB stock valuation for the company's overall valuation and market capitalisation.
EQL PHARMA AB - Asset Composition Analysis
Current Asset Composition (March 2026)
EQL PHARMA AB's total assets of €850.89 Million consist of 47.5% current assets and 52.5% non-current assets. Review EQL PHARMA AB debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 10.2% |
| Accounts Receivable | €92.74 Million | 10.9% |
| Inventory | €200.53 Million | 23.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €441.11 Million | 51.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2026)
This chart illustrates how EQL PHARMA AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 7JK share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EQL PHARMA AB's current assets represent 47.5% of total assets in 2026, a decrease from 51.9% in 2022.
- Cash Position: Cash and equivalents constituted 10.2% of total assets in 2026, down from 17.3% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 46.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 51.8% of total assets.
EQL PHARMA AB Competitors by Total Assets
Key competitors of EQL PHARMA AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
EQL PHARMA AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.92 | 1.81 | 1.24 |
| Quick Ratio | 0.97 | 1.00 | 0.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €193.64 Million | €179.23 Million | €45.79 Million |
EQL PHARMA AB - Advanced Valuation Insights
This section examines the relationship between EQL PHARMA AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.35 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 5.2% |
| Total Assets | €850.89 Million |
| Market Capitalization | $59.21 Million USD |
Valuation Analysis
Below Book Valuation: The market values EQL PHARMA AB's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: EQL PHARMA AB's assets grew by 5.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for EQL PHARMA AB (2022–2026)
The table below shows the annual total assets of EQL PHARMA AB from 2022 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | €850.89 Million ≈ $994.78 Million |
+5.20% |
| 2025-03-31 | €808.82 Million ≈ $945.60 Million |
+116.40% |
| 2024-03-31 | €373.76 Million ≈ $436.96 Million |
+30.82% |
| 2023-03-31 | €285.70 Million ≈ $334.01 Million |
+20.10% |
| 2022-03-31 | €237.89 Million ≈ $278.12 Million |
-- |
About EQL PHARMA AB
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.